JAK Inhibitors Versus Biologic Disease-Modifying Antirheumatic Drugs: Which Is More Effective for Rheumatoid Arthritis Pain?
作者信息
Weiland Abigail, Lee Yvonne C
机构信息
Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
出版信息
Arthritis Rheumatol. 2025 Mar;77(3):241-243. doi: 10.1002/art.43026. Epub 2024 Oct 29.
Abstract
摘要
相似文献
1
JAK Inhibitors Versus Biologic Disease-Modifying Antirheumatic Drugs: Which Is More Effective for Rheumatoid Arthritis Pain?JAK抑制剂与生物改善病情抗风湿药：哪种对类风湿性关节炎疼痛更有效？
Arthritis Rheumatol. 2025 Mar;77(3):241-243. doi: 10.1002/art.43026. Epub 2024 Oct 29.
2
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.类风湿关节炎中Janus激酶抑制剂与生物改善病情抗风湿药的疗效及安全性比较：一项系统评价与网状Meta分析
Ther Adv Musculoskelet Dis. 2021 Mar 21;13:1759720X21999564. doi: 10.1177/1759720X21999564. eCollection 2021.
3
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States.美国类风湿关节炎患者使用生物制剂类改善病情抗风湿药物的经济负担。
Expert Rev Pharmacoecon Outcomes Res. 2022 Dec;22(8):1231-1241. doi: 10.1080/14737167.2022.2117690. Epub 2022 Sep 6.
4
Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis.改善病情抗风湿药与细胞毒性药物在类风湿关节炎治疗中的作用。
Am J Med. 1988 Oct 14;85(4A):39-44. doi: 10.1016/0002-9343(88)90361-0.
5
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.接受生物改善病情抗风湿药物治疗反应不佳的类风湿关节炎患者中，upadacitinib 对比 abatacept 的患者报告结局：一项 3 期试验的 12 周和 24 周结果。
Arthritis Res Ther. 2022 Jun 24;24(1):155. doi: 10.1186/s13075-022-02813-x.
6
[Reduction in the need for glucocorticoids on the background of therapy with biologic disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis: evidence from real clinical practice].[类风湿关节炎中生物性疾病改善抗风湿药物和 Janus 激酶抑制剂治疗背景下糖皮质激素需求的减少：来自真实临床实践的证据]
Ter Arkh. 2024 Jun 3;96(5):465-470. doi: 10.26442/00403660.2024.05.202701.
7
Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study.与生物改善病情抗风湿药相比，JAK抑制剂对类风湿关节炎疼痛缓解的有效性：一项瑞典全国队列研究的结果
Arthritis Rheumatol. 2025 Mar;77(3):253-262. doi: 10.1002/art.43014. Epub 2024 Oct 25.
8
Safety of biological disease-modifying antirheumatic drugs in rheumatoid arthritis.类风湿关节炎中生物改善病情抗风湿药物的安全性。
Farm Hosp. 2021 Dec 11;46(1):15-20.
9
Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.类风湿关节炎患者静脉血栓栓塞的风险：启动改善病情抗风湿药物治疗时的情况
Am J Med. 2015 May;128(5):539.e7-17. doi: 10.1016/j.amjmed.2014.11.025. Epub 2014 Dec 20.
10
Disease-modifying antirheumatic drugs other than methotrexate in rheumatoid arthritis and seronegative arthritis.类风湿关节炎和血清阴性关节炎中除甲氨蝶呤之外的改善病情抗风湿药。
Curr Opin Rheumatol. 2008 May;20(3):251-6. doi: 10.1097/BOR.0b013e3282fb7caa.
本文引用的文献
1
Effectiveness of JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs on Pain Reduction in Rheumatoid Arthritis: Results From a Nationwide Swedish Cohort Study.与生物改善病情抗风湿药相比，JAK抑制剂对类风湿关节炎疼痛缓解的有效性：一项瑞典全国队列研究的结果
Arthritis Rheumatol. 2025 Mar;77(3):253-262. doi: 10.1002/art.43014. Epub 2024 Oct 25.
2
Baricitinib ameliorates inflammatory and neuropathic pain in collagen antibody-induced arthritis mice by modulating the IL-6/JAK/STAT3 pathway and CSF-1 expression in dorsal root ganglion neurons.巴瑞替尼通过调节背根神经节神经元中的白细胞介素 6（IL-6）/Janus 激酶（JAK）/信号转导和转录激活因子 3（STAT3）通路和脑脊液 1（CSF-1）表达来改善胶原抗体诱导的关节炎小鼠的炎症性和神经病理性疼痛。
Arthritis Res Ther. 2024 Jun 15;26(1):121. doi: 10.1186/s13075-024-03354-1.
3
Synovial fibroblast gene expression is associated with sensory nerve growth and pain in rheumatoid arthritis.滑膜成纤维细胞基因表达与类风湿关节炎中的感觉神经生长和疼痛有关。
Sci Transl Med. 2024 Apr 10;16(742):eadk3506. doi: 10.1126/scitranslmed.adk3506.
4
The effect of tofacitinib on residual pain in patients with rheumatoid arthritis and psoriatic arthritis.托法替布对类风湿关节炎和银屑病关节炎患者残留疼痛的影响。
RMD Open. 2022 Sep;8(2). doi: 10.1136/rmdopen-2022-002478.
5
Identifying and Managing Nociplastic Pain in Individuals With Rheumatic Diseases: A Narrative Review.识别和管理风湿性疾病患者的神经病理性疼痛：叙述性综述。
Arthritis Care Res (Hoboken). 2023 Oct;75(10):2215-2222. doi: 10.1002/acr.25104. Epub 2023 Mar 16.
6
Patient-reported outcomes of upadacitinib versus abatacept in patients with rheumatoid arthritis and an inadequate response to biologic disease-modifying antirheumatic drugs: 12- and 24-week results of a phase 3 trial.接受生物改善病情抗风湿药物治疗反应不佳的类风湿关节炎患者中，upadacitinib 对比 abatacept 的患者报告结局：一项 3 期试验的 12 周和 24 周结果。
Arthritis Res Ther. 2022 Jun 24;24(1):155. doi: 10.1186/s13075-022-02813-x.
7
NIH's Helping to End Addiction Long-term Initiative (NIH HEAL Initiative) Clinical Pain Management Common Data Element Program.美国国立卫生研究院的“助力长期终结成瘾倡议”（NIH HEAL倡议）临床疼痛管理通用数据元素项目。
J Pain. 2022 Mar;23(3):370-378. doi: 10.1016/j.jpain.2021.08.005. Epub 2021 Sep 9.
8
Physician Prescribing Patterns and Risk of Future Long-Term Opioid Use Among Patients With Rheumatoid Arthritis: A Prospective Observational Cohort Study.类风湿关节炎患者的医生处方模式与未来长期阿片类药物使用风险：一项前瞻性观察队列研究。
Arthritis Rheumatol. 2020 Jul;72(7):1082-1090. doi: 10.1002/art.41240.
9
Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial.托法替布联合或不联合甲氨蝶呤，或阿达木单抗联合甲氨蝶呤治疗类风湿关节炎的患者报告结局：一项 IIIB/IV 期试验。
RMD Open. 2019 Oct 1;5(2):e001040. doi: 10.1136/rmdopen-2019-001040. eCollection 2019.
10
Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.乌帕替尼治疗甲氨蝶呤应答不足的类风湿关节炎患者的 III 期、双盲、随机对照研究结果。
Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Epub 2019 Aug 28.
Zotero 插件